Amanda Briscoe brings global expertise in regulatory affairs, quality assurance, and reimbursement, integrating regulatory, clinical, and financial strategy to accelerate approvals, optimize pricing, and secure durable market access. Her leadership is anchored in rigorous market analysis, portfolio optimization, and scalable commercialization frameworks that drive long-term shareholder value. A recognized industry leader, she leverages a global network of strategic partners and key opinion leaders to strengthen competitive positioning and sustain commercial success.

Dain Syverson is a Los Angeles native and now based in Atlanta, Dain is the President & Founder of The Syverson Group, LLC (TSG). He serves as the primary search executive engaging with clients in the Diagnostics, Medical Device, Medical Products, Biotechnology, Life Sciences, Pharmaceutical, Dental and Medical Distribution sectors. Dain’s clients include Fortune 500, high growth mid-cap, privately held, private equity group and venture capital-backed firms with focus on Board members; C level; Divisional President and General Management; Vice President and Director Level responsibilities.

Dain’s unique combination of recent business and relevant market experience, key relationships within the industry, ability to assess and attract interest of top executive talent and negotiate mutually acceptable terms & conditions for TSG clients and candidates is unrivaled in the talent acquisition industry.

Prior to founding TSG, Dain served as an Executive Vice President & Partner for over 10 years at a start up search firm where he served as an Officer of the company, led the organization into numerous new verticals, was personally consistently ranked in the Top 1% nationally, built a successful Retained Search offering and developed a reputation in the talent acquisition market for high integrity & authenticity, transparency, tireless work ethic and exceptional performance.

Prior to his talent acquisition start up experience, Dain’s corporate background consisted of over 13 years with Abbott Labs, Diagnostics Division inclusive of executive level responsibilities in General Management, Global & Tactical Marketing, Corporate Accounts, Sales & Sales Management and International Operations. During Dain’s corporate career, he was promoted to increased scopes of responsibility ten (10) times and relocated on seven (7) occasions throughout the U.S. and Europe.

Richard Pines founded Structured Alpha Solutions LLC in 2019 to help innovative healthcare companies accelerate the growth of their businesses and achieve their financial and operational objectives. To date, Structured Alpha Solutions has been hired by both public and private healthcare companies. Previously, Richard Pines co- founded Athyrium in 2008 and served as a Partner and member of the investment committee, helping to raise ~$3.7B of AUM across three funds in less than a decade. Mr. Pines sourced and identified attractive investment opportunities through his deep network of contacts within the healthcare industry. During his time at Athyrium, Mr. Pines was the sole partner on the following healthcare investments: Paradigm Spine (Acquired), BioFire Diagnostics (Acquired), Verenium (Acquired), Universal Biosensors (technology acquisition), Retrophin, Synarc-Biocore (Acquired), Apollo Endosurgery, Cipher Pharmaceuticals, Medicrea (Acquired), HLS Therapeutics, Recro Pharma and Veloxis (Acquired).

Chris Hughes has been in the medical device industry for 30 years. He founded and is the President & CEO of OsteoRemedies®, LLC. Chris has led this company with a vision to be the premier choice for surgeons by providing simple solutions to complex disorders focused on revision and infection remedies. He has held various leadership roles throughout his career starting with 4 years of active duty as a Captain, in the United States Army. Since 1993, he has been in the medical device industry in sales, marketing, business development, and executive management. Chris held many executive roles at Medtronic Spine & Biologics before his tenure as President of Paradigm Spine, LLC, and then President of CMS, LLC, a medical device distribution entity. Chris earned his Bachelor of Science degree at the University of Tampa and a Master of Business Administration degree from Chaminade University. Chris furthered his Executive Education by attending courses at The Wharton School of Business at the University of Pennsylvania and the Darden School of Business at the University of Virginia. Over his career, Chris has held several appointments as a board member and volunteer, including Co-Chair of the Children’s Brain Tumor Foundation of New York City and Board Chairman of One Family Memphis / Memphis Rox.

Brad Fernald is a distinguished medical device executive with a passion and proven track record of launching disruptive and innovative startup companies and technologies in the medical field. As the US President of Omniscient Neurotechnology, Brad is currently leading the charge in using AI and machine learning to revolutionize the diagnosis and treatment of neurological and psychiatric diseases by leveraging brain data. Before joining Omniscient Neurotechnology, Brad held a senior executive role at Synaptive Medical, where he oversaw the development of commercial and product strategies for their surgical robotics and imaging businesses. To date, Synaptive has raised over $253M in funding. Prior to Synaptive, Brad spearheaded the development of key clinical applications and commercial strategies of an MRI- guided laser ablation technology for Visualase, a Houston-based startup, which was later acquired by Medtronic for $105M at over 10x equity invested. Brad holds a degree in Mathematics from the University of Florida and a graduate degree in Biomedical Engineering from Florida International University.

Gary Cantrell brings more than 25 years as an information technology executive. Gary served as Global CIO of Jabil, a leading provider of design engineering and manufacturing solutions to numerous industries including healthcare with 260,000 employees in 30 countries. As CIO, he partnered with business leaders to improve operational efficiency, transition to cloud-based solutions and digital transformation. Previously, Gary served as CIO of Textron, a global network of aircraft, defense, industrial and finance businesses providing innovative solutions. Gary led Global IT, risk and supply chain management encompassing $500M annual investment. He has a B.S. and M.B.A. from the University of Dayton has completed Executive education at Wharton, and Advanced Analytics at University of South Florida.

John (Jack) Bierly, MD has a diverse background in both healthcare and real estate development. Dr. Bierly founded both the Southeast Eye Specialist (SEES Group) and Scenic Land Companies. Dr. Bierly has extensive experience in the de-novo start-up of ophthalmic surgery centers as well as medical office buildings.

He has also been a founding partner in Southeast Medical Properties, Surgery Center of Athens, Eye Surgery Center of Chattanooga, and Southeast Eye Surgery Center of Knoxville. He is a general partner and board member in Scenic Land Investment Management as well as Scenic Land Company, and Scenic Land Development. He has been intimately involved in the rebranding of Canyon Ridge Resort to Mclemore Resort, and has helped guide the development of the clubhouse, a new 245 key Hilton Curio Collection Canyon Cloud Hotel (scheduled to open in February 2024) and the building of a new golf course, the Outpost (scheduled summer of 2024). The Course at Mclemore has the distinction of winning the best 18th hole for Golf Digest in 2020 and shares this award with Pebble Beach (1980) and Harbour Town Links (2000). In 2017, he helped lead his company to a recapitalization with a private equity company, Flexpoint Ford.

He is currently the President of Southeast Eye Specialists (SEES), and serves on the SEES Group Board since 2017 as well as Scenic Land Companies Boards. He holds a B.A. from Johns Hopkins University, an M.D. from Weill Cornell Medical College, and an M.B.A. from Emory University.

Simmy Pappachen is Blue Wellington’s Chief of Staff, and brings a strong entrepreneurial and operational background to the position. Her experience spans business development, media, and wellness platforms, giving her a well-rounded perspective on growth, execution, and organization management.

Simmy founded and managed an international bespoke luxury goods company from the ground up and was eventually featured in the Home & Garden section of the New York Times. In her role as company manager she oversaw operations, partnerships, and brand development amid the early emergence of social media marketing. Simmy has also worked with the Baruch College Public Relations Department in New York City, Psychology Today magazine, and The Therapy Directory, where she developed broad experience across communications, platform growth, and institutional messaging in the health space.

Simmy’s background and experience inform her practical and steady approach as Blue Wellington’s Chief of Staff where she works closely with leadership to clarify priorities, navigate processes, and focus on operational growth objectives.

Dr. Reid Maclellan, M.D. is the Founder and CEO of Cortina Health, Inc, an artificial intelligence company with a mission to restore the care in healthcare and improve quality of life for both patients and physicians. Reid is also an Instructor of Surgery at both Harvard Medical School and Boston Children’s Hospital, where he practices and teaches translational medical research. As a key opinion leader in the fields of healthcare technology, vascular anomalies, and lymphedema, he frequently is invited to lecture both nationally and internationally.

Dr. Maclellan completed a general surgery internship at the University of Tennessee College of Medicine Chattanooga. He then completed plastic surgery clinical and research fellowships at Harvard Medical School and Boston Children’s Hospital. He graduated magna cum laude with a B.S. from the University of Alabama at Birmingham. He received his M.D. from the University of Alabama School of Medicine and a post-doctoral Master in Medical Sciences Degree in translational medical research from Harvard Medical School.

Keith Knutsson is Founder and Chief Executive Officer of Blue Wellington, LLC, a life sciences and medical technology accelerator focused on developing and commercializing proprietary technologies. Keith is a visionary leader, skilled fundraiser, entrepreneur, and operator with over 25 years of experience in operations, financial management, and strategic growth across global markets. Keith has led and advised on complex transactions and consolidation strategies internationally and across industries.

Earlier in his career, Keith played a pivotal role in supporting the valuation and negotiation of the sale of Dollar Rent A Car to the Chrysler Corporation and advised on the development and expansion of the EuroDollar Rent a Car network, which became Europe’s largest privately held car rental company.

In addition to his operational leadership, Keith has served in executive roles within family offices, private equity, and institutional investment platforms across the United States, Europe, and Asia. He has led transactions exceeding $3.2 billion and has been a principal investor and advisor in significant commercial and residential real estate ventures, including Bulgari Hotels and Sodipierre Finance.